<DOC>
	<DOCNO>NCT01791478</DOCNO>
	<brief_summary>This phase I trial study side effect best dose PI3K inhibitor BYL719 give together letrozole treat patient hormone receptor-positive metastatic breast cancer . The PI3K inhibitor BYL719 may stop growth tumor cell block protein need cell growth . Hormone therapy use letrozole may fight breast cancer block use estrogen tumor cell . Giving PI3K inhibitor BYL719 together letrozole may kill tumor cell</brief_summary>
	<brief_title>BYL719 Letrozole Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : To determine safety tolerability BYL719 give combination endocrine therapy post-menopausal patient hormone receptor-positive metastatic breast cancer determine : I . Dose limit toxicity ( DLTs ) first 4 week treatment ( cycle 1 ) . II . Maximum tolerate dose ( MTD ) BYL719 ( PI3K inhibitor BYL719 ) give combination letrozole . III . Highest tolerate dose - ability tolerate BYL719 letrozole total 8 week without development : - Hyperglycemia ( fast glucose &gt; 200 mg/dL ) 2 week row despite optimal medical treatment - CTC Grade 3 &gt; rash 2 week row despite optimal medical treatment - CTC Grade 2 &gt; GI toxicity 2 week row despite optimal medical treatment - CTC Grade 2 &gt; serum creatinine , bilirubin , AST , ALT elevation baseline 2 week row despite optimal medical treatment SECONDARY OBJECTIVES : To determine anti-tumor effect combination endocrine therapy BYL719 post-menopausal patient hormone receptor-positive metastatic breast cancer assessing : I . Progression free survival ( PFS ) . II . Objective response rate ( ORR ) . III . Clinical benefit rate ( complete response [ CR ] +partial response [ PR ] +stable disease [ SD ] &gt; = 6 month ) . EXPLORATORY OBJECTIVES : I. Pharmacokinetics BYL719 combination letrozole : Plasma concentration-time profile derive basic pharmacokinetic ( PK ) parameter BYL719 letrozole , include limited area plasma concentration-time curve time zero last measurable concentration ( AUC0-tlast ) , AUC curve infinite time ( AUC0-inf ) , maximum observed concentration ( Cmax ) , time peak concentration ( Tmax ) , clearance bioavailability ( CL/F ) , apparent volume distribution ( Vz/F ) terminal half-life ( t1/2 ) PK parameter deem appropriate . II . Correlation response alteration PI3K pathway : Mutational analysis PIK3CA ( exon 9 20 ) , phosphatase tensin homolog ( PTEN ) , AKT1 formalin-fixed paraffin block ( FFPB ) previous surgery fresh-frozen biopsy ( available ) patient enrol trial . OUTLINE : This open-label phase Ib dose-escalation study PI3K inhibitor BYL719 combination letrozole post-menopausal patient ER+ metastatic breast cancer . Patients receive BYL719 orally ( PO ) daily ( QD ) letrozole PO QD . Courses repeat every 4 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Inclusion Criteria Patients must provide informed write consent . Patients must &gt; /= 18 year age . ECOG performance status 0 1 . Clinical stage IV invasive mammary carcinoma , ERpositive and/or PRpositive immunohistochemistry ( IHC ) HER2 negative ( IHC ISH ) . Patients may either measurable nonmeasurable disease , allow . A minimum 10 patient trial ( ~50 % ) need PIK3CA mutation cancer Patients must least one line endocrine therapy metastatic setting , diagnose metastatic breast cancer within 1 year adjuvant endocrine therapy . There limit line prior treatment metastatic setting . Patients must available tissue ( archive formalinfixed paraffin embed block ( FFPB ) fresh frozen tissue original diagnosis metastatic setting ) correlative study . Tissue need locate available time registration ( tissue need submit within 3 week study initiation ) . Patients able start study drug without tissue availability . Life expectancy ≥ 6 month Patients must adequate hematologic , hepatic , renal function . All laboratory test must obtain less 1 week study entry . This include : 1 . ANC &gt; /= 1,500/mm3 2. platelet count &gt; /=100,000/mm3 3 . HgB ≥ 9 g/dL 4 . Creatinine ≤ 1.5x ULN 5 . INR ≤ 2 6 . Fasting plasma glucose ≤ 140 mg/dL 7 . HgBA1C ≤ 8 % 8 . Total Serum Bilirubin ≤ 1.5 x ULN ( Patients know Gilbert Syndrome , total bilirubin ≤ 3.0 x ULN , direct bilirubin ≤ 1.5 x ULN ) 9 . SGOT , SGPT ≤ 3 X ULN liver metastasis present 10 . SGOT , SGPT ≤ 5 X ULN liver metastasis present Patients must able swallow retain oral medication . Patients must postmenopausal . Postmenopausal female subject define prior protocol enrollment follow : 1 . Subjects least 55 year age ; OR 2 . Subjects 55 year age naturally ( spontaneous ) amenorrhea least 12 month folliclestimulating hormone ( FSH ) value ≥ 40 IU/L estradiol level &lt; /= 20 IU/L ; OR 3 . Prior bilateral oophorectomy ; OR 4 . Prior radiation castration amenorrhea least 6 month NOTE : Treatment luteinizing hormonereleasing hormone ( LHRH ) agonist ( goserelin acetate leuprolide acetate ) permit induction ovarian suppression . Patients must complete screen assessment outline protocol . Exclusion Criteria Locally recurrent resectable breast cancer . Any kind malabsorption syndrome significantly affect gastrointestinal function . Patients clinically manifest diabetes mellitus ( treat and/or clinical sign fast glucose &gt; /= 140 mg/dL / 7.8 mmol/L ) , history gestational diabetes mellitus document steroidinduced diabetes mellitus . Patients receive radiation therapy &lt; /= 2 week prior study entry . Patients receive prior radiotherapy must recover toxicity ( ≤ grade 1 ) induce treatment . Patients receive systemic anticancer therapy chemotherapy , immunotherapy and/or biologic therapy &lt; /= 4 week prior study entry . Concurrent anticancer therapy ( chemotherapy , immunotherapy , biologic therapy ) one specify protocol permit study participation . Patients must discontinue cancer therapy 4 week prior first dose study medication , well recover toxicity ( ≤ grade 1 , except alopecia ) induce previous treatment . Any investigational drug discontinue 4 week prior first dose study medication . Prior hormonal / endocrine therapy &lt; /= 2 week prior study entry . Patients must recover toxicity &gt; grade 1 , except alopecia . Prior therapy PI3K inhibitor . Prior use Akt mTOR inhibitor allow . Patients receive herbal medication &lt; /= 2 week prior study entry . Herbal medication include , limited : St. John 's wort , Kava , ephedra ( huang ) , gingko biloba , dehydroepiandrosterone ( DHEA ) , yohimbe , saw palmetto , ginseng . Use drug CYP3A4 modifier Patients currently receive medication know risk prolong QT interval induce Torsades de Pointes ( TdP ) treatment either discontinue switched different medication prior start study drug treatment . Patients family history congenital long QT syndrome Patients abnormal calcium , potassium , magnesium level adequately correct within normal range prior initiation study drug Uncontrolled intercurrent illness include , limited : 1. ongoing active infection require parenteral antibiotic 2. impairment lung function ( COPD &gt; grade 2 , lung condition require oxygen therapy ) 3. symptomatic congestive heart failure ( class III IV New York Heart Association classification heart disease ) 4 . Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % 5. unstable angina pectoris , angioplasty , stenting , myocardial infarction within 6 month 6. uncontrolled hypertension within 2 week study initiation ( systolic blood pressure &gt; 180 mm Hg diastolic blood pressure &gt; 110 mm Hg , find two consecutive measurement separate 1 2week period despite adequate medical support ) 7. clinically significant cardiac arrhythmia ( multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia symptomatic require treatment [ National Cancer Institute Common Terminology Criteria Adverse Events , Version 4.0 , grade 3 ] 8 . QTcF ≥ 480 msec screen EKG 9. know history QT/QTc prolongation Torsades de Pointes ( TdP ) 10 . ST depression elevation ≥ 1.5 mm 2 lead 11 . Diarrhea cause ≥ CTCAE grade 2 12. psychiatric illness/social situation would compromise patient safety limit compliance study requirement include maintenance compliance/pill diary 13. patient symptomatic brain metastasis ( patient history brain metastasis must clinically stable 4 week completion radiation treatment ) 14. patient know history chronic liver renal failure 15. patient know history chronic acute pancreatitis Individuals race ethnic group eligible trial . There bias towards age race clinical trial outline . This trial open accrual woman .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>-Metastatic breast cancer , PI3K inhibitor , Endocrine therapy</keyword>
</DOC>